The midday digest of notable stocks reported on ReNet Japan Group's fundraising through a capital alliance, while ReproCELL finalized its clinical development plan for GPC-1 CAR-T therapy.
ReproCELL completed its face-to-face consultation with the Pharmaceuticals and Medical Devices Agency (PMDA) after the close of trading on the 19th and finalized the clinical trial implementation plan based on the discussions. The trial is scheduled to be conducted through Ki-CONNECT at Kyoto University Hospital, and preparations are under way for the submission of the clinical trial notification form. Development is being carried out with support from the Japan Agency for Medical Research and Development (AMED).
ReNet Japan Group expects to raise up to approximately ¥5.448 billion by issuing new shares and stock acquisition rights through a third-party allotment. The funds will be used to build a nationwide collection platform, expand its handling of used IT equipment and pursue M&A. The company has announced capital and business alliances with JX Metals Circular Solutions, SG Holdings and PCS Wireless.
Aiming announced that its listed market segment will change from the Growth Market to the Standard Market, effective on the 26th, and that no specific impact on its earnings forecasts has been disclosed. Shirai Electronics announced an upward revision to its earnings forecasts for the fiscal year ending March 2027, raising its forecast for operating profit from ¥850 million to ¥1.8 billion and indicating that it expects to increase its dividend from ¥20 to ¥28. The company also announced its withdrawal from the SPET business.
Koei Tecmo Holdings raised its first-half earnings forecasts, increasing operating profit from ¥7.0 billion to ¥11.5 billion and ordinary profit from ¥12.0 billion to ¥25.0 billion. Strong sales of major titles released in the previous fiscal year and back-catalogue titles are believed to have been the main factors. SE H&I raised its first-half operating profit forecast from ¥420 million to ¥750 million and its full-year forecast from ¥850 million to ¥1.1 billion, with earnings from its investment management business contributing to the results.
SoftBank Group fell sharply for a second consecutive session, while the Tokyo market was broadly weak as moves in the US market had already been priced in. GMO-GS was viewed positively after announcing an upward revision to its net profit forecast for the fiscal year ending December 2026 on the previous day. Net profit was raised from the previous forecast of ¥1.05 billion to ¥1.31 billion, annual dividends from ¥59.67 to ¥74.35, and a gain on the sale of ¥440 million was recorded.